Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04216134 · ClinicalTrials.gov registry record · Phase 1
68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04216134 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 19 participants.
The verdict
NCT04216134, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects of 68GA-PSMA-11 PET imaging in patients with prostate cancer that has come back (recurrent). Gallium (68Ga) is a radiotracer that binds to a molecule, PSMA, that is found in abundance on most prostate cancer cells. PSMA is short for 'prostate specific membrane antigen'. Diagnostic procedures, such as 68GA-PSMA-11 PET imaging, may help measure a patient's response to earlier treatment, and may help plan the best treatment for prostate cancer.
Interventions
- PROCEDURE Positron Emission Tomography
- DRUG Gallium Ga 68-labeled PSMA-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2022-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04216134
The ClinicalTrials.gov registry entry for NCT04216134 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Positron Emission Tomography is the first listed.
NCT04216134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04216134 about?
NCT04216134 is a clinical study titled "68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer". This phase I trial studies the side effects of 68GA-PSMA-11 PET imaging in patients with prostate cancer that has come back (recurrent). Gallium (68Ga) is a radiotracer that binds to a molecule, PSMA, that is found in abundance on most prostate cancer cells. PSMA is short for 'prostate specific memb...
What is the current status of trial NCT04216134?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-12-12. Estimated completion is 2022-12-09.
What interventions are being tested in trial NCT04216134?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Gallium Ga 68-labeled PSMA-11 (DRUG).
Who is sponsoring clinical trial NCT04216134?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.